Table 2.
Clinical outcomes and complications
| Rituximab N=25 |
No Rituximab N=25 |
p value | ||
|---|---|---|---|---|
| DSA Rebound <2 weeks post-transplant | 0.77 | |||
| No. patients | 9 (36%) | 11 (44%) | ||
| Strength of Rebound: | FCXM+ | 4 (16%) | 5 (20%) | |
| FCXM−, DSA+ | 5 (20%) | 6 (24%) | ||
| DSA Persistence at 1 year: | No. patients | 13 | 10 | 0.57 |
| class I | 4 | 6 | ||
| class II | 5 | 3 | ||
| class I & II | 4 | 1 | ||
| Serum Creatinine (mean ± SD) | ||||
| 1 year | 1.10 ± 0.30 | 1.26 ± 0.39 | 0.21 | |
| 2 year | 1.07 ± 0.22 | 1.28 ± 0.53 | 0.10 | |
| Infections ≤ 1 year | No. patients | 11 | 7 | 0.38 |
| Bacterial | No. infections | 15 | 6 | |
| Viral | 10 | 4 | ||
| Fungal | 2 | 0 | ||
| Total infections | 27 | 10 | 0.08 | |
| Acute rejection1 ≤ 3 months | No. patients | 19 | 14 | 0.23 |
| CMR | No. episodes | 8 | 2 | |
| Subclinical CMR | 4 | 3 | ||
| Total | 12 | 5 | ||
| AMR | 3 | 4 | ||
| Subclinical AMR | 1 | 2 | ||
| Total | 4 | 6 | ||
| Mixed CMR & AMR | 2 | 2 | ||
| Subclinical mixed | 5 | 2 | ||
| Total | 7 | 4 | ||
| Transplant glomerulopathy | ||||
| No. Patients (< 2 years) | 4 | 2 | 0.17 | |